Human Apolipoprotein H Antibody (IgG) ELISA Kit (Sandwich ELISA)
Catalog Number: LS-F67372-1
1 plate / $591.00
Reactivity: Human
Detection Method Colorimetric
Format: 96-Well Strip Plate
Immunohistochemistry of paraffin-embedded human small intestine using antibody at 1:100 dilution. This image was taken for the unconjugated form of this product. Other forms have not been tested.
ARL4D Antibody
Primary AntibodyLSBio Guarantee
| Antibody: | Rabbit Polyclonal |
| Applications: | Enzyme-Linked Immunosorbent Assay, Immunohistochemistry (general), Immunohistochemistry, Paraffin |
| Reactivity: | Human |
| Format: | Liquid |
$300.00each
Catalog Number: LS-C369269-50
Catalog Number: LS-C369269
For bulk orders or custom formulations:
Request a QuoteOverview
- Description
- ARL4D antibody LS-C369269 is an unconjugated rabbit polyclonal antibody to human ARL4D. Validated for ELISA and IHC. Cited in 1 publication.
- Application
- ELISA, IHC, IHC-P
- Reactivity
- Hu
- Intended Use
- Research Use Only
- Guarantees
- This antibody carries the LSBio 100% Guarantee. ✓
- Category
- Antibodies > Primary Antibodies > Polyclonal Antibodies
- Alternative Names
- ADP-ribosylation factor-like 6 | ADP-ribosylation factor 4-like | ARF4L | ARL4D
- UniProt Number
- P49703
- NCBI GenBank
- NM_001661 | NP_001652.2
- SwissProt
- P49703
Target
- Target
- Human ARL4D
- Antigen Species
- Human
- Epitope
- Human ARL4D.
- Gene Name
- ARL4D
Antibody
- Host Species
- Rabbit
- Clonality
- Polyclonal
- Isotype
- IgG
Immunogen
- Immunogen
- Recombinant human ADP-ribosylation factor-like protein 4D protein.
- Immunogen Type
- Recombinant Immunogen
Format
- Conjugate/Label
- Unconjugated
- Format
- Liquid
- Formulation
- PBS, pH 7.4, 0.03% Proclin 300, 50% glycerol.
- Concentration
- 3 mg/mL
- Preservative
- Yes
- Purification Method
- Caprylic Acid / Ammonium Sulfate Precipitation
Storage & Handling
- Storage Conditions
- Short term: -20°C; Long term: -80°C; Avoid freeze-thaw cycles.
- Recommended Storage Buffer
- PBS
Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors. H O Ramdani, M Falk, L C Heukamp, S Schatz, M Tiemann, C Wesseler, L Diehl, E Schuuring, H J M Groen, F Griesinger. Pathology, research and practice. 2021 November;227:153651. PubMed: 34673351
